The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
Drug interactions in single or combined applications;
Drug resistance to antimicrobial and anticancer drugs;
Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
Pharmacogenetics and pharmacogenomics;
Precision medicine in infectious disease therapy and in cancer therapy;
Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
The journal welcomes proposals for special issues and supplements, encouraging interested parties to get in touch to discuss their proposals.
Journal metrics
Usage
57K annual downloads/views
Citation metrics
1.9 (2023) Impact Factor
2.0 (2023) 5 year IF
3.7 (2023) CiteScore (Scopus)
0.531 (2023) SNIP
0.439 (2023) SJR
Speed/acceptance
36 days avg. from submission to first
decision
37 days avg. from submission to first
post-review decision
11 days avg. from acceptance to online
publication
53% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Giuseppe Curigliano (Department of Experimental Oncology, European Institute of Oncology IRCCS, 20139 Milan, Italy 2. Department of Oncology and Hemato-Oncology, University of Milano, 20140 Milan, Italy)
Romano Danesi (Department of Chemotherapy and Pharmacology, University of Pisa, Italy)
Antonello Di Paolo (Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy)
Raffaella Giavazzi (Laboratory of Biology and Treatment of Metastasis, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy)
Antonio Giordano (Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Department of Biology, Temple University, Philadelphia, USA)
Elisa Giovanetti (Amsterdam UMC, VU University Medical Center, Laboratory Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands)
Georg Hempel (Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, University of Muenster, Muenster, Germany)
Bashir A Lwaleed (Department of Urology, University of Southampton, Southampton, UK)
Luciano Martelotto (Development Laboratory, ACE; South Australian Immunogenomics Cancer Institute; Faculty of Health and Medical Sciences, Adelaide University, Canada)
Stefania Nobili (Department of Health Sciences, University of Florence, Italy)
José M. Padrón (BioLab, Instituto Universitario de Bio-Orgánica Antonio González (IUBO-AG), Universidad de La Laguna, Spain)
Godefridus J Peters (Medical Oncology Research Lab, VU University, Netherlands)
Jean Louis Pujol (Thoracic Oncology Unit, Institute Montepellier Academic Hospital, France)
Carlo Riccardi (Department of Clinical Medicine, Pathology and Pharmacology, University of Perugia, Italy)
Jacques Robert (University of Bordeaux, Bordeaux, France)
Rafael Rosell (Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Spain)
Gianni Sava (Department of Life Sciences, University of Trieste, Italy)
Giovanni Scambia (Department of Women's, Children's and Public Health Sciences, Catholic University of the Sacred Heart, Rome, Italy)
Giuseppe Toffoli (CRO National Cancer Institute, Aviano, Italy)
Eric Van Cutsem (Digestive Oncology Department, University Hospitals Leuven and KU Leuven, Belgium)
Paul Workman (Cancer Therapeutics Unit, Cancer Research UK, London, UK)
Nadia Zaffaroni (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
Abstracting and indexing
Journal of Chemotherapy is included in the following services:
Chemical Abstracts
Current Contents - Clinical Medicine
EMBASE/Excerpta Medica
MEDLINE
PubMed
Research Alert®
Science Citation Index
Scopus
Open access
Journal of Chemotherapy is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy) and our publisher Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy) and our publisher Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy) and our publisher Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy) and our publisher Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![HRB Open Research is a platform for HRB-funded researchers to rapidly publish their research outputs in an open and accessible way.]({"type":"image" , "src" : "/sda/112432/HRB-KB.jpg"})